12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alogliptin regulatory update

Takeda said it will delay MAA submissions for alogliptin and alogliptin/Actos (SYR-322-4833) to treat Type II diabetes from mid-2009 to 2012 in order to conduct an additional long-term study for alogliptin. The company said the 2-year study will enroll 2,500 patients and compare alogliptin to glipizide plus metformin. Takeda...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >